|
|
| Product Name: | 3BDO | | Synonyms: | 3BDO;3BDO, 97%, Activator for mTOR, Autophagy inhibitor;Pentonic acid, 2,3-dideoxy-5-O-(2-nitrophenyl)-2-(phenylmethyl)-, γ-lactone;3BDO >=98% (HPLC);3-Benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one;Autophagy,3BDO,mTOR,Apoptosis,Mammalian target of Rapamycin,Inhibitor,inhibit;3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one | | CAS: | 890405-51-3 | | MF: | C18H17NO5 | | MW: | 327.33 | | EINECS: | | | Product Categories: | | | Mol File: | 890405-51-3.mol |  |
| storage temp. | 2-8°C | | solubility | DMSO: 65 mg/ml | | form | oil | | color | colorless to light brown |
| Uses | 3BDO has been used to investigate the potential effects of metformin on inflammatory lung injury. | | Biochem/physiol Actions | 3BDO is a cell-permeable, orally bioavailable, non-toxic butyrolactone derivative that is shown to competitively bind FKBP1A (FK506-binding protein 1A, 12 kDa) in a reversible manner, and suppress autophagy via the mTOR pathway. 3BDO inhibits both LPS- and oxLDL-induced autophagy in HUVECs, increases TIA1 phosphorylation, and reduces autophagosomes number. It is reported to be brain permeant, and significantly decreases atherosclerosis development in apoE-/-?mice (100 mg/kg, q.d., p.o.). 3BDO increases IDE and neprilysin levels, lowers amyloid-β deposition in an AβPP/PS1 transgenic mouse model of Alzheimer′s disease, and alleviates memory deficits. |
| | 3BDO Preparation Products And Raw materials |
|